Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 431-433

  Eskens, Ferry A L M ^a,d   Levitt, Nicky C ^b   Sparreboom, Alex ^a   Choi, Les ^c   Mather, Richard ^c   Verweij, Jaap ^a   Harris, Adrian L ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CGS 27023A; MATRIX METALLOPROTEINASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TARGETING; FOLLOW UP; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR;

ADMINISTRATION, ORAL; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FASTING; HUMANS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; NEOPLASMS; POSTPRANDIAL PERIOD; PROTEASE INHIBITORS; PYRAZINES; SULFONAMIDES;

EID: 0033982644     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Denis, L. J., and Verweij, J. Matrix metalloproteinase inhibitors: present achievements and current prospects. Investig. New Drugs, 15: 175-185, 1997.
2. Levitt, N. C., Eskens, F., Propper, D. J., Harris, A. L., Denis, L., Ganesan, T. S., Mather, R. A., McKinley, L., Planting, A., Talbot, D. C., Van Beurden, V., Van der Burg, M., Wilner, S., and Verweij, J. A phase one pharmacokinetic study of CGS 27023A, a matrix metalloproteinase inhibitor. Proc. Am. Soc. Clin. Oncol., 17: 213a, 1998.